ANKRD22 Polyclonal antibody

ANKRD22 Polyclonal Antibody for IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

IHC, ELISA

Conjugate

Unconjugated

Cat no : 24035-1-AP

Synonyms

ANKRD2, Ankyrin repeat domain-containing protein 22, ankyrin repeat domain 22

---

Validation Data Gallery

• 

  IHC staining of human stomach using 24035-1-AP

  Immunohistochemical analysis of paraffin-embedded human stomach tissue slide using 24035-1-AP (ANKRD22 antibody) at dilution of 1:200 (under 10x lens).

• 

  IHC staining of human stomach using 24035-1-AP

  Immunohistochemical analysis of paraffin-embedded human stomach tissue slide using 24035-1-AP (ANKRD22 antibody) at dilution of 1:200 (under 40x lens).

---

Tested Applications

• Positive IHC detected in: human stomach tissue; Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

• Immunohistochemistry (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

24035-1-AP targets ANKRD22 in IHC, ELISA applications and shows reactivity with human samples.

• Tested Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: ANKRD22 fusion protein Ag21248
• Full Name: ankyrin repeat domain 22
• Calculated Molecular Weight: 191 aa, 22 kDa
• GenBank Accession Number: BC021671
• Gene Symbol: ANKRD22
• Gene ID (NCBI): 118932
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen Affinity purified
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Ankyrin repeat domain-containing protein 22 (ANKRD22) is a novel N-myristoylated protein with a predicted single-pass transmembrane domain. ANKRD22 could potentially act as a novel therapeutic target for non-small cell lung cancer (NSCLC) (PMID: 28667340).